Qian-Xin Chen1, Yuan-Zhong Yang2, Zhuo-Zhi Liang1, Jia-Li Chen1,3, Yue-Lin Li1,4, Zi-Yi Huang1, Zi-Jin Weng5, Xiao-Fang Zhang5, Jie-Xia Guan5, Lu-Ying Tang5, Jing-Ping Yun6, Ze-Fang Ren7. 1. School of Public Health, Sun Yat-Sen University, 74 Zhongshan 2nd Rd, Guangzhou, 510080, China. 2. The Sun Yat-Sen University Cancer Center, Guangzhou, 510080, China. 3. Guangzhou Institute of Dermatology, Guangzhou, 510095, China. 4. The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510080, China. 5. The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510630, China. 6. The Sun Yat-Sen University Cancer Center, Guangzhou, 510080, China. yunjp@sysucc.org.cn. 7. School of Public Health, Sun Yat-Sen University, 74 Zhongshan 2nd Rd, Guangzhou, 510080, China. renzef@mail.sysu.edu.cn.
Abstract
PURPOSE: Results of previous studies on the associations between Forkhead box A1 (FOXA1) expression in breast cancer tissues and the prognosis varied depending on the follow-up durations. The present study would investigate whether there is a time-varying effect of FOXA1 in breast cancer tissues on the prognosis. METHODS: FOXA1 expressions were evaluated in 1041 primary invasive breast tumors with tissue microarrays by immunohistochemistry. Cox models with restricted cubic splines and Kaplan-Meier survival analysis were used to examine the associations between FOXA1 and the prognosis. Flexible parametric models were applied to explore the time-varying effect of FOXA1. RESULTS: Overall, the association between FOXA1 expression and the prognosis was not significant but varied on the time of follow-up. Compared to FOXA1 ≤ 270 of H-score, the hazard ratios (HRs) of death for those with 271-285 of FOXA1 expression increased from 0.35 (95% CI 0.14-0.86) at 6 months after diagnosis to 2.88 (95% CI 1.35-6.15) at 120 months with a crossover at around 36 months. Similar patterns were also observed for FOXA1 > 285 of H-score and for progression free survival (PFS). Moreover, when allowed both FOXA1 and estrogen receptor (ER) to change over time in the model (considering that ER had a similar time-varying effect), these time-varying effects remained for FOXA1 on both overall survival (OS) (P < 0.01) and PFS (P = 0.01) but were attenuated for ER (P = 0.13 for OS). CONCLUSIONS: This study revealed an independent time-varying effect of FOXA1 on breast cancer prognosis, which would provide an insight into the roles of FOXA1 as a marker of breast cancer prognosis and may help optimize the medication strategies.
PURPOSE: Results of previous studies on the associations between Forkhead box A1 (FOXA1) expression in breast cancer tissues and the prognosis varied depending on the follow-up durations. The present study would investigate whether there is a time-varying effect of FOXA1 in breast cancer tissues on the prognosis. METHODS: FOXA1 expressions were evaluated in 1041 primary invasive breast tumors with tissue microarrays by immunohistochemistry. Cox models with restricted cubic splines and Kaplan-Meier survival analysis were used to examine the associations between FOXA1 and the prognosis. Flexible parametric models were applied to explore the time-varying effect of FOXA1. RESULTS: Overall, the association between FOXA1 expression and the prognosis was not significant but varied on the time of follow-up. Compared to FOXA1 ≤ 270 of H-score, the hazard ratios (HRs) of death for those with 271-285 of FOXA1 expression increased from 0.35 (95% CI 0.14-0.86) at 6 months after diagnosis to 2.88 (95% CI 1.35-6.15) at 120 months with a crossover at around 36 months. Similar patterns were also observed for FOXA1 > 285 of H-score and for progression free survival (PFS). Moreover, when allowed both FOXA1 and estrogen receptor (ER) to change over time in the model (considering that ER had a similar time-varying effect), these time-varying effects remained for FOXA1 on both overall survival (OS) (P < 0.01) and PFS (P = 0.01) but were attenuated for ER (P = 0.13 for OS). CONCLUSIONS: This study revealed an independent time-varying effect of FOXA1 on breast cancer prognosis, which would provide an insight into the roles of FOXA1 as a marker of breast cancer prognosis and may help optimize the medication strategies.
Entities:
Keywords:
Breast cancer; FOXA1; Prognosis; Time-varying effects; Tissue microarray
Authors: Antoni Hurtado; Kelly A Holmes; Caryn S Ross-Innes; Dominic Schmidt; Jason S Carroll Journal: Nat Genet Date: 2010-12-12 Impact factor: 38.330
Authors: Caryn S Ross-Innes; Rory Stark; Andrew E Teschendorff; Kelly A Holmes; H Raza Ali; Mark J Dunning; Gordon D Brown; Ondrej Gojis; Ian O Ellis; Andrew R Green; Simak Ali; Suet-Feung Chin; Carlo Palmieri; Carlos Caldas; Jason S Carroll Journal: Nature Date: 2012-01-04 Impact factor: 49.962
Authors: André Albergaria; Joana Paredes; Bárbara Sousa; Fernanda Milanezi; Vítor Carneiro; Joana Bastos; Sandra Costa; Daniella Vieira; Nair Lopes; Eric W Lam; Nuno Lunet; Fernando Schmitt Journal: Breast Cancer Res Date: 2009-06-23 Impact factor: 6.466